More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is the most common primary malignancy of the bone marrow.1, The 5-year survival rate for MM patients has increased from 25% in 1975 to almost 40% due to newer and more effective drugs, such as the immunomodulatory agents (IMiDs) thalidomide and […]
Tag Archives: transplant
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
- Monoclonal gammopathy of undetermined significance (MGUS)
- Asymptomatic (smoldering/indolent) myeloma
- solitary plasmacytoma of the bone
- Extramedullary plasmacytoma
- Light chain myeloma
- Non-secretory myeloma
- Osteosclerotic myeloma (POEMS syndrome)
- Waldenstrom macroglobulinemia
- Light chain amyloidosis
- Plasma cell leukemia
- What Is Multiple Myeloma? January 10, 2019
-
Video Updates June 26, 2018
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects March 5, 2017
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients March 5, 2017
- Outcomes in Multiple Myeloma Patients Evaluated March 5, 2017
- What Is Multiple Myeloma? January 10, 2019
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo March 19, 2011
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting November 23, 2011
- Understanding Myeloma News About Secondary Cancers and Clotting May 28, 2012
-
Dedication of “Determination” June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma
ASCO
B-cell maturation antigen
BCMA
Biomarker
Bortezomib
bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory
Carfilzomib
Dedication
HevyLite; immunoglobulins; multiple myeloma; outcomes
IMBCR
Kyprolis
lenalidomide
monoclonal antibodies
more is not better
Multiple Myeloma
myeloma
Overall survival
Pomalyst
proteasome inhibitors
Revlimid
Secondary Cancers
TRAF6
transplant
update
April 10, 2014
0 Comments